Document is current

Any future updates will be listed below

Phase II study of R–CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study

Crossref DOI link: https://doi.org/10.1186/s40880-019-0403-7

Published Online: 2019-10-16

Published Print: 2019-12

Update policy: https://doi.org/10.1002/crossmark_policy

About CrossMark